ArticleTherapeutic advances in medical oncology2025
Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
Chieh-Lung Cheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.